Compare Essex Property Trust, Inc. (ESS) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Essex Property Trust, Inc. trades at $297.98 (market cap $18.82B), while Vertex Pharmaceuticals Incorporated trades at $481.63 (market cap $121.09B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 6.4× Essex Property Trust, Inc.'s market cap, and Essex Property Trust, Inc. pays a 3.54% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| ESS | VRTX | |
|---|---|---|
Market Cap | $18.82B | $121.09B |
Sector | Real Estate | Health |
52-Week High | $298.33 | $529.59 |
52-Week Low | $239.61 | $366.54 |
Enterprise Value | $25.54B | $115.83B |
Dividend Yield | 3.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Essex Property Trust (ESS) trades at $293.32, down 1.61% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 30.03% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights include the upcoming Q2 2026 earnings release and inclusion in the Russell Microcap Index, reflecting positive momentum.
The outlook for ESS is cautiously optimistic, driven by robust West Coast rental demand and AI-driven employment growth. Risks include elevated debt levels and Seattle market weakness. Analysts maintain a mixed consensus with a $294.25 price target, suggesting limited near-term upside from current levels amid balanced sentiment.
Vertex Pharmaceuticals (VRTX) trades at $476.31, down 0.82% over 24 hours, with a bullish technical signal despite mixed moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $4.47, and maintains robust profitability with a net income margin of 35.51%. Recent news highlights a $10 billion acquisition of Crinetics Pharmaceuticals, aimed at expanding its endocrinology portfolio with potential peak sales of over $5 billion.
The outlook remains positive with analyst consensus favoring a buy rating (83.92%) and a price target of $538, suggesting 13% upside. Key risks include integration challenges from the Crinetics deal and reliance on cystic fibrosis treatments, while strong cash flow and earnings growth support long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
